Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of an active surveillance system by the FDA to observe patterns of quinine sulfate use and adverse hematologic outcomes in CMS Medicare data.
Houstoun M, Reichman ME, Graham DJ, Nambiar S, Shamsuddin H, Jones SC, Cao K, Wernecke M, Lam C, Worrall CM, MaCurdy TE, Kelman JA. Houstoun M, et al. Among authors: wernecke m. Pharmacoepidemiol Drug Saf. 2014 Sep;23(9):911-7. doi: 10.1002/pds.3644. Epub 2014 May 28. Pharmacoepidemiol Drug Saf. 2014. PMID: 24872151
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA. Graham DJ, et al. Among authors: wernecke m. Circulation. 2015 Jan 13;131(2):157-64. doi: 10.1161/CIRCULATIONAHA.114.012061. Epub 2014 Oct 30. Circulation. 2015. PMID: 25359164
Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
Graham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, Southworth MR, Wei Y, Liao J, Goulding MR, Mott K, Chillarige Y, MaCurdy TE, Worrall C, Kelman JA. Graham DJ, et al. Among authors: wernecke m. JAMA Intern Med. 2016 Nov 1;176(11):1662-1671. doi: 10.1001/jamainternmed.2016.5954. JAMA Intern Med. 2016. PMID: 27695821
Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare.
Wang C, Kane R, Levenson M, Kelman J, Wernecke M, Lee JY, Kozlowski S, Dekmezian C, Zhang Z, Thompson A, Smith K, Wu YT, Wei Y, Chillarige Y, Ryan Q, Worrall C, MaCurdy TE, Graham DJ. Wang C, et al. Among authors: wernecke m. JAMA Intern Med. 2016 Dec 1;176(12):1818-1825. doi: 10.1001/jamainternmed.2016.6520. JAMA Intern Med. 2016. PMID: 27775769
Dabigatran Compared With Rivaroxaban vs Warfarin-Reply.
Graham DJ, Wernecke M, Kelman JA. Graham DJ, et al. Among authors: wernecke m. JAMA Intern Med. 2017 May 1;177(5):743-744. doi: 10.1001/jamainternmed.2017.0567. JAMA Intern Med. 2017. PMID: 28460105 No abstract available.
Antihypertensive drug associated angioedema: effect modification by race/ethnicity.
Reichman ME, Wernecke M, Graham DJ, Liao J, Yap J, Chillarige Y, Southworth MR, Keeton S, Goulding MR, Mott K, Kelman JA. Reichman ME, et al. Among authors: wernecke m. Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1190-1196. doi: 10.1002/pds.4260. Epub 2017 Jul 19. Pharmacoepidemiol Drug Saf. 2017. PMID: 28722207
70 results